Goldman initiated coverage on Bruker with a new price target
$BRKR
Biotechnology: Laboratory Analytical Instruments
Industrials
Goldman initiated coverage of Bruker with a rating of Sell and set a new price target of $40.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/10/2025 | $60.00 | Peer Perform → Outperform | Wolfe Research |
| 12/9/2025 | $40.00 | Sell | Goldman |
| 11/20/2025 | $60.00 | Buy | Rothschild & Co Redburn |
| 5/22/2025 | $40.00 | Buy → Neutral | Citigroup |
| 12/19/2024 | $72.00 | Buy | Guggenheim |
| 12/10/2024 | $66.00 | Neutral | UBS |
| 12/5/2024 | $60.00 | Sell → Neutral | Goldman |
| 10/15/2024 | $75.00 | Overweight | Barclays |
New iNTApharma system enables rapid, native‑state size and concentration measurements with single‑particle sensitivity for viral, vesicle, and nanoscale bioparticle workflows Bruker Corporation today announced the launch of iNTApharma, a label‑free characterization platform that provides single‑particle sensitivity for the quantitative analysis of nanoscale bioparticles in native aqueous media. Introduced at SLAS 2026 in Boston, iNTApharma delivers size and concentration measurements within minutes, supporting research, therapy development and quality control workflows that require direct, native‑state assessment of bio-nanoparticle populations without labeling or chemical modifications.
At SLAS2026, Chemspeed Technologies, a leader in the automation and digitalization of R&D and QC laboratories, and SciY, a leader in scientific and laboratory management software focused on lab standardization and AI-readiness, today introduce their open Self‑Driving Lab (SDL) platform. Their Self-Driving Lab platform is designed to accelerate research and development (R&D), quality control (QC) and chemical and biomolecular manufacturing workflows. The SDL enables lab managers to operationalize autonomous, AI‑orchestrated experimentation through vendor‑agnostic integration that unites modular precision automation, scientific analysis and lab management software, complete lab digitization a
Bruker Corporation (NASDAQ:BRKR, BRKRP)) today announced that its Board of Directors ("Board") has approved payment of a quarterly cash dividend in the amount of $3.9844 per share on the Company's 6.375% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the "Mandatory Convertible Preferred Stock Dividend"). The Mandatory Convertible Preferred Stock Dividend will be paid on March 2, 2026 to stockholders of record as of February 15, 2026. About Bruker Corporation – Leader of the Post-Genomic Era Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's hi
Wolfe Research upgraded Bruker from Peer Perform to Outperform and set a new price target of $60.00
Goldman initiated coverage of Bruker with a rating of Sell and set a new price target of $40.00
Rothschild & Co Redburn initiated coverage of Bruker with a rating of Buy and set a new price target of $60.00
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
3 - BRUKER CORP (0001109354) (Issuer)
8-K - BRUKER CORP (0001109354) (Filer)
8-K - BRUKER CORP (0001109354) (Filer)
144 - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
Bruker Corporation (NASDAQ:BRKR, BRKRP)) today announced that its Board of Directors ("Board") has approved payment of a quarterly cash dividend in the amount of $3.9844 per share on the Company's 6.375% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the "Mandatory Convertible Preferred Stock Dividend"). The Mandatory Convertible Preferred Stock Dividend will be paid on March 2, 2026 to stockholders of record as of February 15, 2026. About Bruker Corporation – Leader of the Post-Genomic Era Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's hi
Bruker Corporation (NASDAQ:BRKR) today announced it will report fourth quarter and fiscal year 2025 financial results before market opening on Thursday, February 12, 2026. The Company will host a conference call and webcast at 8:30 a.m. Eastern Standard Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the "Q4 2025 Earnings Webcast" hyperlink in the "Events & Presentations" section. A slide presentation will be referenced during the webcast and will be posted to the Company's website shortly before the webcast begins. Investors can also listen to the earnings webcast via telephone by dialing 1-888-43
TOFWERK is a profitable innovator in compact, ultra-fast time-of-flight (TOF) mass spectrometry for real-time air and semiconductor cleanroom monitoring, food, flavors & fragrances markets, and FIB-TOF accessories for electron microscopes The ultra-sensitive Vocus™ TOF-MS is customizable for real-time air and cleanroom monitoring applications Microwave-induced plasma (MIP)-TOF systems with atto-to-femtogram detection limits for real-time quantification of trace elements and metals Proprietary flow tube-based VUV CI sources for positive and negative trace organics, inorganics and PFAS contaminants Focused Ion Beam (FIB)-TOF accessories for scanning electron microscopes Bruker
ST. LOUIS, April 23, 2025 (GLOBE NEWSWIRE) -- Solis Agrosciences, the trusted partner for high-quality AgTech research services, announced that it has hired Crystal Winkeler as Chief Business Officer. Winkeler will join Solis on May 1 to drive the company's commercial team and help lead efforts to develop and acquire new offerings. "Solis has assembled an impressive team, offerings, and customer base," said Winkeler. "I am thrilled to join the business at this important growth stage." "Crystal is a proven talent who is confident, capable, and credible in front of customers and stakeholders," said Charlie Bolten, CEO of Solis Agrosciences. "She is a huge addition and will help drive our c
Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with
Strategic partnership expands Biognosys' services to include Alamar's NULISA assays as well as joint scientific research in biofluid-based proteomicsComplementary value of Biognosys' DIA-MS unbiased proteomics platform and Alamar's game-changing immunoassay platforms to be presented at the AACR 2024 Annual Meeting ZURICH, Switzerland and FREMONT, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Biognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a company powering precision proteomics to enable the earliest detection of disease, are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomic